SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Share based compensation expenses, grant in period | $ 518,161 | $ 224,206 | $ 1,586,534 | $ 1,443,788 |
Options Granted To Employees | 220,391 | 392,891 | 175,000 | |
Common Shares From Convertible Debentures And Related Accrued Interest | 53,427 | 52,957 | 53,427 | 52,957 |
Current Federal Deposit Insurance | $ 250,000 | |||
External Expenses | 1,123,454 | $ 1,065,293 | ||
Internal Expenses | 1,299,517 | 841,816 | ||
Amortization Of The R & D Obligation | $ 702,045 | $ 350,099 | ||
Common Shares Issuable Upon The Exercise Of Outstanding Stock Options And Warrants | 6,509,129 | 6,322,385 | 6,509,129 | 6,322,385 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No definition available.
|
X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|